Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%

NCT ID: NCT00176943

Last Updated: 2014-02-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-10-31
• Study Completion Date: 2002-08-31

Brief Summary

It is thought that alopecia areata occurs as the result of an inappropriate response of the body's own immune system to certain substances in or around the hair follicle. We will be examining the efficacy of Aldara Cream 5% in treating extensive alopecia areata and observe its affect on the hair follicle.

Detailed Description

We will examine how the application of Aldara Cream 5% daily for 6 months will affect the hair follicle and the inflammation present in the skin of patients with alopecia areata. In the study we will obtain additional scalp biopsies to examine how the drug affects the quality and state of activity of the immune cells in the biopsy specimens. This type of information will provide data about the behavior of these inflammatory cells in mediating the hair loss associated with alopecia areata and how this behavior may be effected by Aldara Cream 5% treatment. Such information may be valuable to the successful management of alopecia areata.

Conditions

Alopecia Areata

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Blinding Strategy: NONE

Interventions

Aldara Cream 5%

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Must be in good health.
• No topical or systemic treatment for alopecia areata for at least 2 weeks prior to study initiation.
• Must be at least 18 years of age and older
• Will have to have extensive scalp alopecia areata (>95% involvement) of less than 2 years duration.
• Willing to refrain from other alopecia areata treatments during the course of the study.
• Will have to agree to shampoo their scalp daily with Free and Clear shampoo. Participant in "Aldara for the Treatment of Extensive Alopecia Areata" study.

Exclusion Criteria

• History of any illness or condition that in the opinion of the investigator might confound the results of the study or pose additional risk to the patient
• Significant abnormalities on screening clinical evaluation.
• Previous use of Aldara Cream 5%.
• A history of drug or alcohol abuse.
• Use of UV radiation including tanning beds and PUVA therapy for treatment of acne, psoriasis, or any other skin condition within 2 months prior to study initiation.
• Use of systemic or topical glucocorticoids, corticosteroids, estrogenic, progestogenic, androgenic or antiandrogen drugs, cyclosporine, FK506 or immunotherapy with DNCB,SADBE or DCP within 6 months of study initiation.
• Alterations in thyroid medication within 6 weeks of study initiation. Pregnant or nursing females. Not participating in the "Aldara for the Treatment of Extensive Alopecia Areata" study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Alopecia Areata Foundation

OTHER

Sponsor Role: collaborator

Hordinsky, Maria K., MD

INDIV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Maria Hordinsky, MD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Marna Ericson, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Locations

University of Minnesota

Minneapolis, Minnesota, United States

Countries

United States

Other Identifiers

0009M64941

Identifier Type: -

Identifier Source: org_study_id